Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor Presented at 2023 AACR-NCI-EORTC International Conference

Press Release Circle Pharma, in collaboration with the laboratory of Violeta Serra, Ph.D., at Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain, recently unveiled preclinical data demonstrating the efficacy of Circle’s oral Cyclin A/B inhibitor macrocycles…

Related Keywords

Spain ,United States ,Hebron ,Israel General ,Israel ,Barcelona ,Comunidad Autonoma De Cataluna ,Peru ,Perou ,American ,Davidj Earp ,Roslyn Patterson ,Violeta Serra ,Williamj Gradishar ,American Society Of Clinical Oncology ,International Conference On Molecular ,Drug Administration ,Hebron Institute Of Oncology ,Hebron Institute ,Molecular Targets ,Circle Pharma ,San Francisco Based Circle Pharma ,Triple Negative Breast Cancer ,Current Practice ,